News

Health Rounds: Semaglutide pill Rybelsus matches heart benefits of injectable versions
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...
Yahoo Finance25d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial ...
Finanznachrichten25d
Novo Nordisk A/S: Rybelsus (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.
Mena FN26d
Novo Nordisk A/S: Rybelsus® (Oral Semaglutide 14 Mg) Demonstrates Superior Reduction In Cardiovascular Events In The SOUL Trial At ACC 2025
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly ...
Yahoo Finance25d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Rybelsus ® reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial 1.
News Medical23d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the risk of major adverse ...
MM&M7d
Eli Lilly’s GLP-1 pill aces late-stage trial days after Pfizer pulls theirs
patients taking Novo’s Rybelsus lost an average of 4.8 pounds with the 7mg drug and 6.8 pounds with the 14mg pill. Lilly’s study found that orforglipron achieved similar weight loss numbers, but from ...
NBC New York25d
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...
Cleveland.com4d
Pull Tab Palooza is coming up at 3 NE Ohio locations
CLEVELAND, Ohio – For those who save pull tabs, who have containers full of the can tops laying around their kitchens, the 2025 Pull Tab Palooza is coming up. The annual palooza, which supports ...
Taiwan News25d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly reduced the ...
Sports Illustrated11d
Jets 'Keeping Close Tabs' On Massive Game-Breaker
One guy the team reportedly is "keeping close tabs" on is Texas A&M EDGE Shemar Stewart, according to ESPN's Rich Cimini. "No. 5. A name to watch: The Jets are keeping close tabs on edge rusher ...